EUVIMEDEUVIMED entdecken
Crossref

An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

Marina Sagud, Dagmar Breznoscakova, Andreja Celofiga, Jana Chihai, Eka Chkonia, Dragana Ristic Ignjatovic, Lidija Injac Stevovic, Miloslav Kopecek, Katrin Kurvits, Nazar Kuzo, Judit Lazáry, Ramunė Mazaliauskienė und 12 weitere

Schizophrenia Research · 2024

DOI: 10.1016/j.schres.2023.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Research, 2024. Verfasst von Marina Sagud und 23 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Zagreb, Zagreb, Croatia; University Hospital Centre Zagreb, Zagreb, Croatia. Electronic address: marinasagud@mail.c…. Hauptthemen laut MEDLINE: Clozapine, Pharmacovigilance, Antipsychotic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To compare the prevalence, regulations, and pharmacovigilance practices of clozapine use in Eastern European countries (except Russia). METHODS: Questionnaires and data from administrative databases (2016 and 2021), package inserts and national guidelines were collected from 21 co-authors from 21 countries. Reports of clozapine adverse drug reactions (ADRs) sent to the global pharmacovigilance database (VigiBase™) were analyzed from introduction to December 31, 2022. RESULTS: Clozapine prescription among antipsychotics in 2021 varied six-fold across countries, from 2.8 % in the Czech Republic to 15.8 % in Montenegro. The utilization of antipsychotics in both 2016 and 2021 was highest in Croatia, and lowest in Serbia in 2016, and Montenegro in 2021, which had half the defined daily dose (DDD)/1000/day compared to the Croatian data. From 2016 to 2021, the prevalence of antipsychotic use increased in almost all countries; the proportion of clozapine use mainly remained unchanged. Differences were detected in hematological monitoring requirements and clozapine approved indications. Only a few national schizophrenia guidelines mention clozapine-induced myocarditis or individual titration schemes. The VigiBase search indicated major underreporting regarding clozapine and its fatal outcomes. By comparison, the United Kingdom had less than half the population of these Eastern European countries but reported to VigiBase more clozapine ADRs by 89-fold and clozapine fatal outcomes by almost 300-fold. CONCLUSION: Clozapine is under-utilized in Eastern European countries. Introducing individualized clozapine treatment schedules may help to maximize clozapine benefits and safety. Major improvement is needed in reporting clozapine ADRs and fatal outcomes in Eastern European countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClozapinePharmacovigilanceAntipsychotic AgentsHumansEurope, EasternSchizophreniaAdverse Drug Reaction Reporting SystemsDatabases, FactualDrug-Related Side Effects and Adverse Reactions

Stichwörter der Autor:innen

Clozapine/administration and dosageClozapine/adverse effectsClozapine/therapeutic useDrug labelingEurope, EasternSchizophrenia

Substanzen

ClozapineAntipsychotic Agents

Autor:innen und Institutionen

  • School of Medicine, University of Zagreb, Zagreb, Croatia; University Hospital Centre Zagreb, Zagreb, Croatia. Electronic address: marinasagud@mail.com.
  • Department of Social and Behavioural Medicine, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia. Electronic address: dbreznoscakova@gmail.com.
  • Department of Psychiatry, University Medical Centre, Maribor, Maribor, Slovenia. Electronic address: Andreja.CELOFIGA@ukc-mb.si.
  • State University of Medicine and Pharmacy Nicolae Testemitanu, Chişinău, Republic of Moldova. Electronic address: jana.chihai@usmf.md.
  • Tbilisi State Medical University, Department of Psychiatry, Tbilisi, Georgia. Electronic address: e.chkonia@tsmu.edu.
  • University of Kragujevac, Faculty of Medical Sciences, Department of Psychiatry, Kragujevac, Serbia. Electronic address: draganaristic4@gmail.com.

Zitieren

APA

Sagud, M., Breznoscakova, D., Celofiga, A., Chihai, J., Chkonia, E., Ristic Ignjatovic, D., Injac Stevovic, L., Kopecek, M., Kurvits, K., Kuzo, N., Lazáry, J., Mazaliauskienė, R., Mladina Perisa, D., Novotni, A., Panov, G., Pikirenia, U., Rădulescu, F. Ș., Sukiasyan, S. G., Taube, M., …, & de Leon, J. (2024). An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance. Schizophrenia Research. https://doi.org/10.1016/j.schres.2023.09.002

Vancouver

Sagud M, Breznoscakova D, Celofiga A, Chihai J, Chkonia E, Ristic Ignjatovic D, et al. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance. Schizophrenia Research. 2024. doi:10.1016/j.schres.2023.09.002

BibTeX
@article{Sagud2024,
  author = {Sagud, Marina and Breznoscakova, Dagmar and Celofiga, Andreja and Chihai, Jana and Chkonia, Eka and Ristic Ignjatovic, Dragana and Injac Stevovic, Lidija and Kopecek, Miloslav and Kurvits, Katrin and Kuzo, Nazar and Lazáry, Judit and Mazaliauskienė, Ramunė and Mladina Perisa, Djurdjica and Novotni, Antoni and Panov, Georgi and Pikirenia, Uladzimir and Rădulescu, Flavian Ștefan and Sukiasyan, Samvel Grant and Taube, Māris and Tomori, Sonila and Wilkowska, Alina and De Las Cuevas, Carlos and Sanz, Emilio J and de Leon, Jose},
  title = {An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance},
  journal = {Schizophrenia Research},
  year = {2024},
  doi = {10.1016/j.schres.2023.09.002}
}
Kostenlos starten →